A. Robinson

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

Richard Gray, Daniel Rea, Kelly Handley et al. · Journal of Clinical Oncology · 2013 · 446 citations

Breast Oncology, Cancer Management, Epidemiology Of Cancer +17

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Stephen Johnston, Lucy Kilburn, David Dodwell et al. · The Lancet Oncology · 2013 · 272 citations · Full text

long-term follow-up of anglian germ cell cancer group surveillance versus patients with stage 1 nonseminoma treated with adjuvant chemotherapy

R.T.D. Oliver, J. Ong, Jonathan Shamash et al. · Urology · 2004 · 107 citations

Long-term Follow-up, Medicine, Cancer Management +7